Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies
Adlai Nortye licensed exclusive worldwide development and commercialization rights to Novartis Pharma AG's buparlisib (BKM120) for all therapeutic, prophylactic, or diagnostic uses, except for certain rights Novartis retains.
- In Vitro Diagnostics
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.